CBI Investment Firm Kineta Selected as a ‘Top 10 Biotech Startup Company’ This Year

[Asia Economy Reporter Jang Hyowon] Kineta, a US immuno-oncology drug development company invested by CBI, has recently been selected as a startup company by the local Life Sciences Review, showing various activities.

Life Sciences Review is a well-known industry journal in the fields of new drugs and medical care, mainly covering individuals and companies that have recently emerged or are leading market trends, and selects outstanding biotech companies annually.

CBI stated, “Kineta was selected as an excellent biotech company of the year by Life Sciences Review due to its research capabilities related to immuno-oncology drugs, the excellence of the PiiONEERTM platform technology that can discover optimized new drug candidates, and the market superiority and potential of the licensed narcotic addiction treatment and anti-VISTA antibody therapy with Genentech.”

Furthermore, Kineta’s CEO Shawn ladonato said, “We are steadily preparing to enter clinical phase 1 for the anti-VISTA antibody therapy, and in the second half of the year, we will advance in the immuno-oncology field by conducting preclinical studies on immuno-oncology drugs such as the CD27 antibody therapy.”

A CBI official said, “Kineta, in which we have invested, is focusing on developing new treatments not only for the survival of cancer patients but also for improving their quality of life. The demand for new treatments for cancer patients remains high, and we believe Kineta’s drugs will play a significant role in improving patient treatment and prognosis,” adding, “We are confident in Kineta’s growth potential and plan to continue targeting the global bio market based on this.”